ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

UDG Udg Healthcare Public Limited Company

1,079.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Udg Healthcare Public Limited Company LSE:UDG London Ordinary Share IE0033024807 ORD EUR0.05 (CDI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 1,079.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
1,078.00 1,079.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
  -
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 1,079.00 GBX

Udg Healthcare Public (UDG) Latest News

Real-Time news about Udg Healthcare Public Limited Company (London Stock Exchange): 0 recent articles

Udg Healthcare Public (UDG) Discussions and Chat

Udg Healthcare Public Forums and Chat

Date Time Title Posts
06/1/202211:31United Drug - no valium here !!612
16/9/200411:34UDG - Excellent results today10

Add a New Thread

Udg Healthcare Public (UDG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Udg Healthcare Public (UDG) Top Chat Posts

Top Posts
Posted at 30/5/2021 08:17 by carcosa
FT:

M&G Investments, the £367bn asset manager, has blasted plans to sell London-listed UDG Healthcare to buyout firm Clayton, Dubilier & Rice, the latest in a series of criticisms of private equity deals by big fund managers.

Shareholders are due to vote in June on the £2.8bn all-cash offer to sell UDG, which provides clinical, commercial, communication and packaging services for the healthcare industry. 

But London-based M&G, which is a top-five shareholder in UDG according to data provider CapitalIQ, said the bid “fails to offer fair value to ordinary shareholders, including the customers on whose behalf we invest”. 

Allianz Global Investors, UDG’s largest shareholder, has also criticised the deal. Earlier this month, Elliott Investment Management, the activist investor, said it had taken a stake in the Dublin-headquartered company. 

The criticism by M&G and AllianzGI comes at a time of growing concern in the UK that listed companies are being sold off too cheaply to private equity firms. 

While fund managers rarely make public statements on companies, some have decided to speak out about deals involving private equity in recent weeks, including Schroders, which criticised transport operator FirstGroup’s planned £3.3bn sale of its US business to Swedish buyout group EQT.

Private equity groups, many of which have raised their largest-ever funds, are targeting the UK stock market with the aim of capitalising on lower valuations in the wake of Brexit and the pandemic. 

Thirteen private equity buyouts of UK-listed companies have been announced since the beginning of 2021, the highest year-to-date figure since 2006, according to figures from Refinitiv. Just two were announced during the same period in 2019. 

Rory Alexander, a fund manager at M&G, said he was concerned that CD&R would benefit from the UDG deal at the expense of ordinary investors.

“The $3.7bn offer does not reflect the potential long term value creation of UDG’s organic growth story, opportunity for strategic acquisitions, consistent cash generation and fortress balance sheet,” he said.

“The material mismatch between the offer price and our opinion of UDG’s true value represents upside transferred away from ordinary shareholders towards the private equity bidder.”

UDG declined to comment. But when the deal was announced on May 12, UDG chair Shane Cooke, said it was an “attractive offer”. He added that it “secures the delivery of future value for shareholders in cash today. The offer reflects the quality, strength and long term performance of UDG’s businesses and its future growth potential”.

CD&R declined to comment.

AllianzGI, which owns 8.6 per cent of UDG’s shares, said earlier this month that the price did “not adequately compensate existing shareholders”, adding that it was the duty of the board to “obtain a fair value for shareholders”.

“AllianzGI firmly believes that the offer is opportunistic and significantly undervalues UDG and its prospects and is not in the best interests of shareholders. Consequently, based on available information, AllianzGI is minded not to accept the current offer despite it being recommended to shareholders by the Board of UDG,” it added.
Posted at 12/5/2021 06:45 by mach100
Very good news. Excellent company and the take out price is juicy for a change. Shows the prospects of the company, The yield was poor so the cash is very welcome. Time for my next project.
Posted at 03/6/2020 12:33 by 3rd eye
UDG Healthcare...........

Interesting to see the forward forecast for the company.

As per the majority of stock it will take a (very small) hit for 30/09/2020 but then in 2021 bounces back with vengeance, with a 16% rise in EPS which would put it on a p/e of 17 and a PEG of 1........in other words a (late) Jim Slater ZULU principle stock.

SEE forward forecasts below.

FORECAST

year Ending Revenue
(€m) Pre-tax(€m) EPS P/E PEG EPS Growth Div Yield

2020-09-30 1,005.48 102.04 36.88p 20.1 -4.8 -4% 11.18p 1.5%
2021-09-30 1,087.20 122.83 42.91p 17.1 1.0 16% 15.01p 2.0%

CHART

SP as moved above the 200 day moving average a bullish sign. In a lovely uptrend.
Posted at 22/5/2020 09:29 by 3rd eye
UDG Broker Forecasts..........

Latest broker views

Date Broker Recomm. Current Price Price when issued Old price New price
22 May 20 Berenberg Buy 692.50 694.00 740.00 880.00
19 May 20 Liberum Capital Buy 692.50 623.50 900.00 -
19 May 20 Peel Hunt Buy 692.50 623.50 1,165.00
Posted at 22/5/2020 09:12 by 3rd eye
UDG Healthcare UDG.. worth a bob or two investment.

UDG valuation is ‘compelling217;, says Berenberg

Healthcare packaging company UDG Healthcare (UDG) is trading on a ‘compelling valuation’ for a market leader, says Berenberg.

Analyst Eoghan Read retained his ‘buy’ recommendation and increased his target price from 740p to 880p. The shares rose 1.6% to 692.5p yesterday.

First-half results from the group beat Read’s forecasts by 6% and he said while it had not been immune from the impact of Covid-19, his ‘confidence in the equity story’ had increased thanks to positive momentum, operating resilience, and the ‘long-term structural drivers evident in the market’.

‘UDG remains one of our top picks in our UK mid-cap business services coverage,’ he said. ‘Trading on a 20% discount to long-term average and US peers, we think it now presents a compelling valuation opportunity for a structurally growing and market-leading operator.’

============================================================================

Lovely uptrend channel on the chart. If it breaks through the ceiling of the channel, next share price target mid term is 730p approx. P/E 19 for 2021, cheap considering the Boom in Bios and health at the moment.
Posted at 31/1/2020 16:20 by brain smiley
UDG organises meeting and events for the drugs industry in China.Will they have to be cancelledand how much profit do they make from them ?
Posted at 02/4/2019 14:25 by mfhmfh
Peel Hunt today reitrratr buy rating and 1,030 target price.
Posted at 26/3/2019 10:33 by brain smiley
Interesting price action;hit 5.45 this morning. Mmmm.
Posted at 19/2/2019 14:55 by brain smiley
Very poor performer.Shorttracker showing a Fund opened a 1.1% short in February;the only short interest in UDG.

Wouldn't be surprised to see more director buying.
Posted at 01/12/2018 14:20 by mfhmfh
share price still below CFO's purchase of 20,000 shares at 740p in August this year.

Sellers all gone I think.

GLA.
Udg Healthcare Public share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock